Wednesday, March 30, 2011 10:37:59 AM
Anyways.... I usually would not post this... but whatever...
I figure it's worth peoples read...
From: Harry Palmin [mailto:hpalmin@novelos.com]
Sent: Monday, March 28, 2011 2:01 PM
To: XXXXX, XXXXX
Cc: slichaw@novelos.com
Subject: RE: NVLT Update 3.1.2011
Hello XXXXX,
I cannot comment beyond publicly available information. We continue to work diligently on implementing the third step of the rebuilding process.
Best,
Harry
________________________________________
From: XXXXX, XXXXX [mailto:XXXXX@XXXX.com]
Sent: Monday, March 28, 2011 1:33 PM
To: Harry Palmin
Cc: slichaw@novelos.com; Steve Lichaw/Cayuga Advisors
Subject: RE: NVLT Update 3.1.2011
Harry,
Thanks. Always good to reaffirm your position.
I’m trying my best to stave away from the daily movements regarding the share price. I believe it is currently indicative of technical trading/market manipulation – the short interest is very high (reaching 89% on last Friday’s trading session); therefore, do not believe it accurately depict future advances/information.
Do you anticipate any press releases prior to 3/31/11 – the due date for the 10-K and additionally, do you expect an extension to be filed based on the current situation at Novelos (i.e. potential negotiations for new funding/acquisition or merger etc…). Per previous e-mails, your team has been able to accomplish the first 2 of the 3 steps within the rebuilding process. Third step being the most difficult (capital raises/product acquisition), but given your Wall Street roots and Stephen Lichaws restructuring, turnaround, M&A and capital raises background – I figure it’s only a matter of time, not if but when.
XXXXX XXXXX
XXXX
From: Harry Palmin [mailto:hpalmin@novelos.com]
Sent: Thursday, March 24, 2011 7:25 PM
To: XXXXX, XXXXX
Cc: slichaw@novelos.com; 'Steve Lichaw/Cayuga Advisors'
Subject: RE: NVLT Update 3.1.2011
Hi XXXXX,
I have not sold any equity shares of Novelos, before or since NOV-002 failed Ph3 in NSCLC.
Best,
Harry
________________________________________
From: XXXXX, XXXXX [mailto:XXXXX@XXXX.com]
Sent: Thursday, March 24, 2011 10:28 AM
To: Harry Palmin
Cc: slichaw@novelos.com; Steve Lichaw/Cayuga Advisors
Subject: RE: NVLT Update 3.1.2011
Harry,
Just want to reconfirm whether you have sold any equity shares since the Phase III failure. Price movement – specifically currently (33.33% drop from yesterdays close) currently at .012 with 512K in volume has me irked.
Any guidance – even the slightest bit here?
XXXXX XXXXX
XXXX
From: Steve Lichaw/Cayuga Advisors [mailto:selichaw@yahoo.com]
Sent: Wednesday, March 23, 2011 12:27 PM
To: XXXXX, XXXXX; Harry Palmin
Cc: slichaw@novelos.com
Subject: Re: NVLT Update 3.1.2011
Nice write up, thanks
Steve Lichaw
201-240-3200
________________________________________
From: "XXXXX, XXXXX" <XXXXX@XXXX.com>
To: Harry Palmin <hpalmin@novelos.com>
Cc: slichaw@novelos.com
Sent: Wed, March 23, 2011 12:23:38 PM
Subject: RE: NVLT Update 3.1.2011
Ok thanks.
Not sure if you’re aware but NOV-002 was mentioned in the following article relating to breast cancer today (3/23/11).
Latest regarding the Women’s Health
XXXXX XXXXX
XXXX
From: Harry Palmin [mailto:hpalmin@novelos.com]
Sent: Monday, March 21, 2011 11:18 AM
To: XXXXX, XXXXX
Cc: slichaw@novelos.com
Subject: RE: NVLT Update 3.1.2011
The filing requirement for 10K is by March 31.
________________________________________
From: XXXXX, XXXXX [mailto:XXXXX@XXXX.com]
Sent: Monday, March 21, 2011 11:14 AM
To: Harry Palmin
Cc: slichaw@novelos.com
Subject: RE: NVLT Update 3.1.2011
Thanks Harry.
Just wanted to know when the 10K is slated to be released.
Thanks.
XXXXX XXXXX
the trend is your friend
Recent CLRB News
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 07/11/2024 09:37:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2024 09:15:21 PM
- Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape • GlobeNewswire Inc. • 06/27/2024 10:40:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:04:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:04:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:03:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:02:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:01:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:01:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:00:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 09:04:30 PM
- Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides • GlobeNewswire Inc. • 05/29/2024 10:40:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/24/2024 08:46:56 PM
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 05/16/2024 10:05:03 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 10:45:17 AM
- Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update • GlobeNewswire Inc. • 05/14/2024 10:40:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 10:32:20 AM
- Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day • GlobeNewswire Inc. • 05/08/2024 10:40:23 AM
- Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024 • GlobeNewswire Inc. • 05/07/2024 10:40:00 AM
- Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update • GlobeNewswire Inc. • 03/27/2024 10:40:00 AM
- Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024 • GlobeNewswire Inc. • 03/20/2024 10:40:00 AM
- Cellectar Biosciences to Present at the 36th Annual Roth Conference • GlobeNewswire Inc. • 03/14/2024 12:52:48 PM
- Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer • GlobeNewswire Inc. • 03/04/2024 11:40:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/15/2024 01:31:57 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:29:43 PM
Peer To Peer Network aka Mobicard™ Launches AI Investor Chatbot Boosting Engagement & Lead Generation on Ihub • PTOP • Jul 15, 2024 8:30 AM
Greenlite Ventures Announces AI Integration into No Limit Platforms • GRNL • Jul 15, 2024 8:00 AM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM